DataSheet_1_Knowledge structure and hotspots research of glioma immunotherapy: a bibliometric analysis.docx

BackgroundGlioma is the most common primary brain tumor. Traditional treatments for glioma include surgical resection, radiotherapy, chemotherapy, and bevacizumab therapy, but their efficacies are limited. Immunotherapy provides a new direction for glioma treatment. This study aimed to summarize the knowledge structure and research hotspots of glioma immunotherapy through a bibliometric analysis.
MethodPublications pertaining to glioma immunotherapy published during the period from 1st January 1990 to 27th March 2023 were downloaded from the Web of Science Core Collection (WoSCC). Bibliometric analysis and visualization were performed using the CiteSpace, VOSviewer, Online Analysis Platform of Literature Metrology, and R software. The hotspots and prospects of glioma immunotherapy research were illustrated via analyzing the countries, institutions, journals, authors, citations and keywords of eligible publications.
ResultsA total of 1,929 publications pertaining to glioma immunotherapy in 502 journals were identified as of 27th March 2023, involving 9,505 authors from 1,988 institutions in 62 countries. Among them were 1,285 articles and 644 reviews. Most of publications were produced by the United States. JOURNAL OF NEURO-ONCOLOGY published the majority of publications pertaining to glioma immunotherapy. Among the authors, Lim M contributed the largest number of publications. Through analyzing keyword bursts and co-cited references, immune-checkpoint inhibitors (ICIs) were identified as the research focus and hotspot.
ConclusionUsing a bibliometric analysis, this study provided the knowledge structure and research hotspots in glioma immunotherapy research during the past 33 years, with ICIs staying in the current and future hotspot. Our findings may direct the research of glioma immunotherapy in the future.

背景：胶质瘤（Glioma）是最常见的原发性脑肿瘤。传统的胶质瘤治疗手段包括手术切除、放疗、化疗以及贝伐珠单抗治疗，但疗效均有限。免疫疗法为胶质瘤治疗提供了全新方向。本研究旨在通过文献计量分析，梳理胶质瘤免疫治疗领域的知识结构与研究热点。
方法：本研究从Web of Science核心合集（Web of Science Core Collection, WoSCC）下载了1990年1月1日至2023年3月27日期间发表的与胶质瘤免疫治疗相关的文献。采用CiteSpace、VOSviewer、文献计量学在线分析平台以及R软件进行文献计量分析与可视化。通过分析符合纳入标准的文献的国家、机构、期刊、作者、被引情况与关键词，阐释了胶质瘤免疫治疗研究的热点与未来展望。
结果：截至2023年3月27日，本研究共筛选得到502种期刊刊载的1929篇胶质瘤免疫治疗相关文献，涉及62个国家的1988家机构的9505名作者。其中包括1285篇研究论文与644篇综述类文献。美国的发文量位居首位。《Journal of Neuro-Oncology》刊载的胶质瘤免疫治疗相关文献数量最多。在作者中，Lim M的发文量最高。通过关键词突现与共被引参考文献分析，免疫检查点抑制剂（immune-checkpoint inhibitors, ICIs）被确定为该领域的研究重点与热点。
结论：本研究通过文献计量分析，阐明了过去33年间胶质瘤免疫治疗领域的知识结构与研究热点，其中免疫检查点抑制剂仍是当前及未来的研究热点。本研究结果可为未来胶质瘤免疫治疗的相关研究提供方向指引。